209 related articles for article (PubMed ID: 10799756)
21. Modulation of the kynurine pathway of tryptophan metabolism in search for neuroprotective agents. Focus on kynurenine-3-hydroxylase.
Pellicciari R; Amori L; Costantino G; Giordani A; Macchiarulo A; Mattoli L; Pevarello P; Speciale C; Varasi M
Adv Exp Med Biol; 2003; 527():621-8. PubMed ID: 15206781
[TBL] [Abstract][Full Text] [Related]
22. The pentylenetetrazole-induced activity in the hippocampus can be inhibited by the conversion of L-kynurenine to kynurenic acid: an in vitro study.
Rozsa E; Robotka H; Nagy D; Farkas T; Sas K; Vecsei L; Toldi J
Brain Res Bull; 2008 Jul; 76(5):474-9. PubMed ID: 18534254
[TBL] [Abstract][Full Text] [Related]
23. Quinolinic acid lesion of the nigrostriatal pathway: effect on turning behaviour and protection by elevation of endogenous kynurenic acid in Rattus norvegicus.
Miranda AF; Sutton MA; Beninger RJ; Jhamandas K; Boegman RJ
Neurosci Lett; 1999 Mar; 262(2):81-4. PubMed ID: 10203236
[TBL] [Abstract][Full Text] [Related]
24. 3-Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum.
Guidetti P; Schwarcz R
Eur J Neurosci; 1999 Nov; 11(11):3857-63. PubMed ID: 10583474
[TBL] [Abstract][Full Text] [Related]
25. Metabolism of [5-3H]kynurenine in the rat brain in vivo: evidence for the existence of a functional kynurenine pathway.
Guidetti P; Eastman CL; Schwarcz R
J Neurochem; 1995 Dec; 65(6):2621-32. PubMed ID: 7595559
[TBL] [Abstract][Full Text] [Related]
26. Systemic administration of 4-chlorokynurenine prevents quinolinate neurotoxicity in the rat hippocampus.
Wu HQ; Lee SC; Schwarcz R
Eur J Pharmacol; 2000 Mar; 390(3):267-74. PubMed ID: 10708733
[TBL] [Abstract][Full Text] [Related]
27. Excitotoxic injury stimulates pro-drug-induced 7-chlorokynurenate formation in the rat striatum in vivo.
Lee SC; Schwarcz R
Neurosci Lett; 2001 May; 304(3):185-8. PubMed ID: 11343833
[TBL] [Abstract][Full Text] [Related]
28. Kynurenine 3-mono-oxygenase activity and neurotoxic kynurenine metabolites increase in the spinal cord of rats with experimental allergic encephalomyelitis.
Chiarugi A; Cozzi A; Ballerini C; Massacesi L; Moroni F
Neuroscience; 2001; 102(3):687-95. PubMed ID: 11226705
[TBL] [Abstract][Full Text] [Related]
29. Production of quinolinic acid and kynurenic acid by human glioma.
Vezzani A; Gramsbergen JB; Speciale C; Schwarcz R
Adv Exp Med Biol; 1991; 294():691-5. PubMed ID: 1837700
[No Abstract] [Full Text] [Related]
30. Xanthurenic Acid Formation from 3-Hydroxykynurenine in the Mammalian Brain: Neurochemical Characterization and Physiological Effects.
Sathyasaikumar KV; Tararina M; Wu HQ; Neale SA; Weisz F; Salt TE; Schwarcz R
Neuroscience; 2017 Dec; 367():85-97. PubMed ID: 29031603
[TBL] [Abstract][Full Text] [Related]
31. Neuroprotective effects of kynurenine-3-hydroxylase inhibitors in models of brain ischemia.
Moroni F; Cozzi A; Peruginelli F; Carpenedo R; Pellegrini-Giampietro DE
Adv Exp Med Biol; 1999; 467():199-206. PubMed ID: 10721057
[TBL] [Abstract][Full Text] [Related]
32. Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types.
Heyes MP; Chen CY; Major EO; Saito K
Biochem J; 1997 Sep; 326 ( Pt 2)(Pt 2):351-6. PubMed ID: 9291104
[TBL] [Abstract][Full Text] [Related]
33. Specific inhibition of kynurenate synthesis enhances extracellular dopamine levels in the rodent striatum.
Amori L; Wu HQ; Marinozzi M; Pellicciari R; Guidetti P; Schwarcz R
Neuroscience; 2009 Mar; 159(1):196-203. PubMed ID: 19138730
[TBL] [Abstract][Full Text] [Related]
34. Enzyme-catalyzed production of the neuroprotective NMDA receptor antagonist 7-chlorokynurenic acid in the rat brain in vivo.
Wu HQ; Salituro FG; Schwarcz R
Eur J Pharmacol; 1997 Jan; 319(1):13-20. PubMed ID: 9030892
[TBL] [Abstract][Full Text] [Related]
35. Studies on the neuroprotective action of kynurenine mono-oxygenase inhibitors in post-ischemic brain damage.
Moroni F; Carpenedo R; Cozzi A; Meli E; Chiarugi A; Pellegrini-Giampietro DE
Adv Exp Med Biol; 2003; 527():127-36. PubMed ID: 15206725
[TBL] [Abstract][Full Text] [Related]
36. Some metabotropic glutamate receptor ligands reduce kynurenate synthesis in rats by intracellular inhibition of kynurenine aminotransferase II.
Battaglia G; Rassoulpour A; Wu HQ; Hodgkins PS; Kiss C; Nicoletti F; Schwarcz R
J Neurochem; 2000 Nov; 75(5):2051-60. PubMed ID: 11032894
[TBL] [Abstract][Full Text] [Related]
37. Systemically administered glucosamine-kynurenic acid, but not pure kynurenic acid, is effective in decreasing the evoked activity in area CA1 of the rat hippocampus.
Robotka H; Németh H; Somlai C; Vécsei L; Toldi J
Eur J Pharmacol; 2005 Apr; 513(1-2):75-80. PubMed ID: 15878711
[TBL] [Abstract][Full Text] [Related]
38. Pharmacologically elevated levels of endogenous kynurenic acid prevent nicotine-induced activation of nigral dopamine neurons.
Erhardt S; Oberg H; Engberg G
Naunyn Schmiedebergs Arch Pharmacol; 2001 Jan; 363(1):21-7. PubMed ID: 11191832
[TBL] [Abstract][Full Text] [Related]
39. Maternal genotype determines kynurenic acid levels in the fetal brain: Implications for the pathophysiology of schizophrenia.
Beggiato S; Notarangelo FM; Sathyasaikumar KV; Giorgini F; Schwarcz R
J Psychopharmacol; 2018 Nov; 32(11):1223-1232. PubMed ID: 30354938
[TBL] [Abstract][Full Text] [Related]
40. Kynurenine 3-hydroxylase inhibition in rats: effects on extracellular kynurenic acid concentration and N-methyl-D-aspartate-induced depolarisation in the striatum.
Urenjak J; Obrenovitch TP
J Neurochem; 2000 Dec; 75(6):2427-33. PubMed ID: 11080194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
